Clinical Trials Logo
  1. Home
  2. Metastatic Renal Cell Cancer
  3. NCT01258348

A Phase 1b Trial in Patients With Renal Cell Cancer

Metastatic Renal Cell Cancer Clinical Trial

Official title:
A Phase 1b Study of LY573636-sodium in Combination With Sunitinib Malate in Patients With Metastatic Renal Cell Cancer

Clinical Trial Summary

The purpose of this study is to determine a safe dose of LY573636-sodium to be given in combination with sunitinib to patients with metastatic Renal Cell Carcinoma (RCC) and to determine any side effects that may be associated with LY573636-sodium and sunitinib combination in this patient population. The tumor response rate will also be assessed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01258348
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 1
Start date July 2008
Completion date February 2012
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02664883 - Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
Completed NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Phase 1
Completed NCT01462214 - Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer Phase 1/Phase 2
Completed NCT02555748 - Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Phase 4
Completed NCT02899078 - Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer Phase 1/Phase 2
Terminated NCT00670748 - Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer Phase 2
Completed NCT01829841 - A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer Phase 2
Active, not recruiting NCT01767636 - Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Phase 2
Terminated NCT02542202 - Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer N/A
Completed NCT02626130 - Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer Early Phase 1
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Active, not recruiting NCT01590069 - Aerosolized Aldesleukin in Treating Patients With Lung Metastases Phase 1
Recruiting NCT01884961 - Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2 Phase 2
Completed NCT02599194 - 18F-FSPG PET/CT for Cancer Patients on Therapy Phase 2
Completed NCT01246843 - Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib N/A
Completed NCT00428220 - A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. N/A
Active, not recruiting NCT03092856 - Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer Phase 2
Completed NCT02843607 - Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer Phase 1/Phase 2
Completed NCT02318771 - Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer Phase 1
Active, not recruiting NCT02689167 - Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma Phase 2